Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03042468 trial: what clinicians have said so far
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
- NCT03042468 ↗
- Completed
- Weill Medical College of Cornell University
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03042468 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03042468 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I/ll Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive Metastatic Castration Resistant Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- 177Lu-PSMA-617; 68Ga-PSMA-HBED-CC
- Arms
- All subjects · Experimental
- Enrollment
- 50
- Primary outcomes
- Number of Subjects With Dose Limiting Toxicity (DLT) of Fractionated Dose of 177Lu-PSMA-617
- Number of Subjects That Achieved Cumulative Maximum Tolerated Dose (MTD) Phase II Dose of 177Lu-PSMA-617
- Recommended Phase II Dose of 177Lu-PSMA-617 in a 2-week Dose-fractionation Regimen
- Sponsor
- Weill Medical College of Cornell University
- Start
- Dec 2016
- Primary completion
- Sep 30, 2021
- Results posted
- Yes
- Registry record
- NCT03042468 · updated Sep 14, 2026
Publications
linked from the registry- Vlachostergios PJ, Niaz MJ, Skafida M, Mosallaie SA, Thomas C, Christos PJ, Osborne JR, Molina AM, Nanus DM, Bander NH, Tagawa ST. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted beta-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19. PubMed 33465252